Resources
About Us
Digital Therapeutics Market by Application (Mental health, Diabetes, Respiratory, Neurology, Gastrointestinal, Cardiovascular, Addiction, Rehabilitation, Oncology, Sleep Disorder), Type (Disease Prevention, Management), End User - Global Forecast to 2030
Report ID: MRHC - 104743 Pages: 198 Jun-2023 Formats*: PDF Category: Healthcare Delivery: 2 to 4 Hours Download Free Sample ReportDigital therapeutics (DTx) delivers evidence-based therapeutic interventions to prevent, manage, or treat a range of patients' physical, mental, and behavioral conditions using high-quality software programs. Digital therapeutics consists of software-as-a-medical devices that support self-managing symptoms.
Clinicians recommend digital therapeutics due to improved patient outcomes and experience. Behavioral changes and self-management improve patients’ overall experience in care management. Therefore, clinicians encourage using digital therapeutics as it generates additional insights, resulting in a comprehensive patient health condition.
The prevalence of chronic diseases and conditions such as diabetes, arthritis, and heart disease is rising globally. According to the WHO, in 2020, the prevalence of chronic diseases globally was estimated at 57%. Each year 41 million people succumb to chronic diseases, accounting for 71% of all deaths globally. Growth in the aging population and changes in social behaviors are major factors driving a steady increase in the number of people suffering from chronic diseases. For example, according to the International Diabetes Federation, in 2019, it was estimated that 19.3% of people aged 65 years and above had diabetes. In North America & the Caribbean, the prevalence of diabetes in people aged 65 years and above increased to 27.0% in 2019 from 26.3% in 2017 and is estimated to be 27.3% in 2030. In Europe, the diabetes prevalence in people aged 65 years and above increased to 24.2% in 2019 from 20.4% in 2017 and is estimated to increase to 24.7% in 2030. Thus, the growing prevalence of chronic diseases is driving the adoption of digital therapeutics solutions for regular health monitoring and treatment.
In 2020, the geriatric population accounted for 9.3% of the global population (Source: United Nations). Similarly, according to the United Nations, developing regions such as Asia, Latin America, and Africa have the highest proportions of the population aged 65 years and above, followed by Europe and North America. The geriatric population is prone to several chronic diseases. Therefore, the growing geriatric population, coupled with the rising burden of chronic diseases, is driving the growth of the digital therapeutics market.
Click here to: Get a Free Sample Copy of this report
Emerging economies worldwide are fueling the demand for healthcare services and treatments due to rapid urbanization, improving healthcare infrastructure, increasing healthcare expenditures, increasing healthcare insurance coverage, rising disposable incomes, and the growing prevalence of non-communicable and infectious diseases.
According to the World Bank, the total population of emerging countries is projected to reach around 3.4 billion by 2050. Additionally, according to the International Diabetes Federation, globally, the number of people with diabetes aged 20–79 reached 537 million in 2021 from 425 million in 2017. This number is further estimated to reach 643 million by 2030. These factors are expected to boost the demand for digital therapeutics.
Growing urbanization and rising GDP per capita in emerging economies such as South Africa, India, Brazil, China, Bangladesh, and Thailand drive the demand for healthcare services and treatments. Growing urbanization indicates higher wages, a better quality of life, and improved access to healthcare services. Therefore, growing urbanization in emerging economies is expected to drive the development of healthcare systems, increasing people’s access to healthcare services, which, in turn, further leads to the proliferation of digital therapeutics in urban regions.
Thus, considering the overall scenario, factors such as the rising number of people suffering from chronic and infectious diseases, population growth, and increasing urbanization are expected to drive the demand for digital therapeutics solutions in emerging countries, creating significant growth opportunities for the companies operating in this market.
Based on type, the digital therapeutics market is segmented into disease management and treatment DTx and disease prevention DTx. In 2023, the disease management and treatment DTx segment is expected to account for the largest share of the digital therapeutics market. The large market share of this segment is attributed to the increased prevalence of chronic diseases, availability of cost-effective digital therapeutics solutions for disease management, increased investments in digital therapeutics, and the need to lower healthcare costs due to the rising economic burden of healthcare costs.
Based on application, the digital therapeutics market is segmented into mental health, diabetes, cardiovascular diseases, gastrointestinal disorders, neurology, rehabilitation and patient care, oncology, respiratory disorders, addiction management, sleep disorders, smoking cessation, and other applications. In 2023, the mental health segment is expected to account for the largest share of the digital therapeutics market. The large market share of this segment is attributed to the growing burden of mental health issues, Cognitive behavioral therapy-based support for mental health issues, and personalized care to the patients. Additionally, employers are increasingly adopting mental health digital therapeutic platforms to increase employee productivity, thereby driving the market.
The key factors contributing to the growth of this segment are the growing prevalence of chronic diseases among patients, the trend of preventive healthcare, and increased awareness of the self-monitoring of diseases among individual consumers.
The large share of this market is attributed to factors such as the increased prevalence of chronic diseases, surge in usage of digital health products, and rise in awareness among government agencies. Additionally, the number of players operating in the U.S. digital therapeutics market is high. North America has multiple digital therapeutic companies, including 2Morrow Inc. (U.S.), Welldoc, Inc. (U.S.), BigHealth (U.S.), Teladoc Health, Inc. (U.S.), and DarioHealth Corp. (U.S.). Additionally, the U.S. government supported digital therapeutics during the COVID-19 pandemic. For example, in April 2020, US Food and Drug Administration (FDA) eased certain premarket requirements for smartphone apps and programs specifically designed to support the treatment of conditions such as anxiety, obsessive-compulsive disorder, insomnia, and depression. These factors have contributed significantly to the large market share of this region in the global digital therapeutics market.
The report includes a competitive landscape based on an extensive assessment of the key strategic developments that led market participants to adopt over the past years. The key players operating in the global digital therapeutics market are Noom, Inc. (U.S.), 2Morrow Inc. (U.S.), GAIA AG (Germany), ResMed Inc. (U.S.), Canary Health (U.S.), Welldoc, Inc. (U.S.), DarioHealth Corp. (U.S.), Akili, Inc. (U.S.), Biofourmis Inc. (U.S.), BigHealth (U.S.), Teladoc Health, Inc. (U.S.), Limbix Health, Inc. (U.S.), Kaia Health Software Inc. (Germany), Glooko, Inc. (U.S.), and Virta Health Corp. (U.S.).
Key questions answered in the report:
The Digital Therapeutics Market involves software-based interventions delivering evidence-based therapeutic programs for managing physical, mental, and behavioral conditions.
The Digital Therapeutics Market is projected to reach $42.98 Billion by 2030, indicating significant growth and increased adoption of digital health solutions.
The market is forecasted to grow at a CAGR of 31.1% from 2023 to 2030, reflecting rapid expansion and increased demand for digital health solutions.
By 2030, the Digital Therapeutics Market size is expected to be $42.98 billion, showcasing the anticipated growth and rising investment in digital health technologies.
Key players include Noom Inc., 2Morrow Inc., GAIA AG, ResMed Inc., Canary Health, Welldoc Inc., and DarioHealth Corp., shaping the market with innovative solutions.
A major trend is the focus on mental health applications, driven by growing awareness and a shift towards preventive and personalized digital health solutions.
Drivers include the rise in chronic diseases, aging population, urbanization in emerging economies, and increased investment in digital health for chronic disease management.
Segments include disease management and treatment DTx, disease prevention DTx, with applications like mental health, diabetes, cardiovascular, and more therapeutic areas.
The global outlook is positive, with growth driven by emerging economies, increasing healthcare demands, and technological advancements enhancing digital health solutions.
The Digital Therapeutics Market is growing rapidly, projected to expand at a CAGR of 31.1% from 2023 to 2030, driven by rising market interest and digital health integration.
The market is projected to grow at a CAGR of 31.1% from 2023 to 2030, reflecting significant growth and increasing adoption of digital therapeutic solutions.
North America holds the highest market share, driven by high digital health adoption, advanced healthcare infrastructure, and strong government support for digital innovations.
1. Market Definition & Scope
1.1. Market Definition
1.2. Market Coverage
1.3. Market Ecosystem
1.4. Currency and Limitations
1.5. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Sizing and Forecasting
2.3.1. Market Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Key Factors Affecting Market Growth
4.2.1. Impact Analysis of DROC
4.2.1.1. Increasing Focus on Preventive Healthcare and Self-testing is Driving the Market
4.2.1.2. Data Privacy Concerns Associated with Digital Therapeutics Applications are Restraining Market Growth
4.2.1.3. Emerging Economies and Growing Product Pipeline is Providing Opportunities for Market Growth
4.2.1.4. Lengthy and Tedious Regulatory Approval Process is Posing a Challenge to the Market’s Growth
4.3. Trends
4.3.1. Partnership of Digital Therapeutics Companies with Pharmaceutical Companies
4.3.2. Integration of Artificial Intelligence (AI) in Digital Therapeutics
4.4. Regulatory and Reimbursement Approval Pathway
4.4.1. U.S.
4.4.2. Germany
4.4.3. France
4.4.4. Belgium
4.4.5. U.K.
4.4.6. China
4.4.7. Japan
4.4.8. South Korea
4.5. Case Study
4.5.1. Connected Inhalers to Reduce Asthma Symptoms (Propeller Health)
4.5.2. Sharp Rees-Stealy Medical Group (U.S.) Improves Outcomes with Diabetes Management Program
4.5.3. Improvement in Self-management of Diseases with Digital Health Solutions
5. Digital Therapeutics Market Assessment—by Type
5.1. Overview
5.2. Disease Management and Treatment DTx
5.3. Disease Prevention DTx
6. Digital Therapeutics Market Assessment—by Application
6.1. Overview
6.2. Mental Health
6.3. Diabetes
6.4. Cardiovascular Diseases
6.5. Gastrointestinal Disorders
6.6. Neurology
6.7. Rehabilitation & Patient Care
6.8. Respiratory Disorders
6.9. Oncology
6.10. Addiction Management
6.11. Sleep Disorders
6.12. Smoking Cessation
6.13. Other Applications
7. Digital Therapeutics Market Assessment—by End Users
7.1. Overview
7.2. Providers
7.3. Individual Consumers
7.4. Employers
7.5. Payers
7.6. Other End Users
8. Digital Therapeutics Market Assessment—by Geography
8.1. Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. U.K.
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe (RoE)
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Rest of Asia-Pacific (RoAPAC)
8.5. Latin America
8.5.1. Brazil
8.5.2. Mexico
8.5.3. Rest of Latin America (RoLATAM)
8.6. Middle East & Africa
9. Competition Analysis
9.1. Introduction
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
9.4.1. Industry Leaders
9.4.2. Market Differentiators
9.4.3. Vanguards
9.4.4. Emerging Companies
9.5. Company Ranking for Global Digital Therapeutics Market (2022)
10. Company Profiles (Company Overview, Financial Snapshot, Product Portfolio, Strategic Developments, SWOT Analysis)
10.1. ResMed Inc.
10.2. Teladoc Health, Inc.
10.3. Noom, Inc.
10.4. DarioHealth Corp.
10.5. GAIA AG
10.6. Biofourmis Inc.
10.7. Virta Health Corp.
10.8. Welldoc, Inc.
10.9. Glooko, Inc.
10.10. 2Morrow Inc.
10.11. Canary Health
10.12. BigHealth
10.13. Akili, Inc.
10.14. Limbix Health, Inc.
10.15. Kaia Healthcare Software Inc.
10.16. Popular Mentions
11. Appendix
11.1. Available Customization
11.2. Related Reports
List of Tables
Table 1 Key Differences Between Digital Health, Digital Medicine, And Digital Therapeutics
Table 2 Market Authorizations of Digital Therapeutics
Table 3 Global Digital Therapeutics Market, by Type, 2021-2030 (USD Million)
Table 4 Global Digital Therapeutics Market for Disease Management and Treatment, by Country/Region, 2021–2030 (USD Million)
Table 5 Global Digital Therapeutics Market for Disease Prevention, by Country/Region, 2021–2030 (USD Million)
Table 6 Global Digital Therapeutics Market, by Applications, 2021-2030 (USD Million)
Table 7 Global Digital Therapeutics Market for Mental Health, by Country/Region, 2021–2030 (USD Million)
Table 8 Global Digital Therapeutics Market for Diabetes, by Country/Region, 2021–2030 (USD Million)
Table 9 Global Digital Therapeutics Market for Cardiovascular Diseases, by Country/Region, 2021–2030 (USD Million)
Table 10 Global Digital Therapeutics Market for Gastrointestinal Disorders, by Country/Region, 2021–2030 (USD Million)
Table 11 Global Digital Therapeutics Market for Neurology, by Country/Region, 2021–2030 (USD Million)
Table 12 Global Digital Therapeutics Market for Rehabilitation and Patient Care, by Country/Region, 2021–2030 (USD Million)
Table 13 Global Digital Therapeutics Market for Oncology, by Country/Region, 2021–2030 (USD Million)
Table 14 Global Digital Therapeutics Market for Respiratory Disorders, by Country/Region, 2021–2030 (USD Million)
Table 15 Global Digital Therapeutics Market for Addiction Management, by Country/Region, 2021–2030 (USD Million)
Table 16 Global Digital Therapeutics Market for Sleep Disorder, by Country/Region, 2021–2030 (USD Million)
Table 17 Global Digital Therapeutics Market for Smoking Cessation, by Country/Region, 2021–2030 (USD Million)
Table 18 Global Digital Therapeutics Market for Other Applications, by Country/Region, 2021–2030 (USD Million)
Table 19 Global Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 20 Global Digital Therapeutics Market for Providers, by Country/Region, 2021–2030 (USD Million)
Table 21 Global Digital Therapeutics Market for Individual Consumers, by Country/Region, 2021–2030 (USD Million)
Table 22 Global Digital Therapeutics Market for Employers, by Country/Region, 2021–2030 (USD Million)
Table 23 Global Digital Therapeutics Market for Payers, by Country/Region, 2021–2030 (USD Million)
Table 24 Global Digital Therapeutics Market for Other End Users, by Country/Region, 2021–2030 (USD Million)
Table 25 Digital Therapeutics Market, by Country/Region, 2021–2030 (USD Million)
Table 26 North America: Digital Therapeutics Market, by Country/Region, 2021–2030 (USD Million)
Table 27 North America: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 28 North America: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 29 North America: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 30 U.S.: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 31 U.S.: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 32 U.S.: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 33 Canada: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 34 Canada: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 35 Canada: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 36 Europe: Digital Therapeutics Market, by Country/Region, 2021–2030 (USD Million)
Table 37 Europe: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 38 Europe: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 39 Europe: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 40 Germany: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 41 Germany: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 42 Germany: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 43 U.K.: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 44 U.K.: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 45 U.K.: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 46 France: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 47 France: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 48 France: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 49 Italy: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 50 Italy: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 51 Italy: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 52 Spain: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 53 Spain: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 54 Spain: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 55 Rest of Europe: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 56 Rest of Europe: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 57 Rest of Europe: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 58 Asia-Pacific: Digital Therapeutics Market, by Country/Region, 2021–2030 (USD Million)
Table 59 Asia-Pacific: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 60 Asia-Pacific: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 61 Asia-Pacific: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 62 China: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 63 China: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 64 China: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 65 Japan: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 66 Japan: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 67 Japan: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 68 India: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 69 India: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 70 India: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 71 Rest of Asia-Pacific: Digital Therapeutics Market, By Type, 2021–2030 (USD Million)
Table 72 Rest of Asia-Pacific: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 73 Rest of Asia-Pacific: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 74 Latin America: Digital Therapeutics Market, by Country/Region, 2021–2030 (USD Million)
Table 75 Latin America: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 76 Latin America: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 77 Latin America: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 78 Brazil: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 79 Brazil: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 80 Brazil: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 81 Mexico: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 82 Mexico: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 83 Mexico: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 84 People (20-79 Y) With Diabetes in Argentina, Colombia, and Chile (in Thousands)
Table 85 Rest of Latin America: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 86 Rest of Latin America: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 87 Rest of Latin America: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 88 Middle East & Africa: Digital Therapeutics Market, by Type, 2021–2030 (USD Million)
Table 89 Middle East & Africa: Digital Therapeutics Market, by Application, 2021–2030 (USD Million)
Table 90 Middle East & Africa: Digital Therapeutics Market, by End User, 2021–2030 (USD Million)
Table 91 Recent Developments, by Company, 2020–2023
List of Figures
Figure 1 Market Ecosystem
Figure 2 Key Stakeholders
Figure 3 Research Process
Figure 4 Secondary Sources Referenced for this Study
Figure 5 Primary Research Techniques
Figure 6 Key Executives Interviewed
Figure 7 Breakdown of Primary Interviews (Supply-Side & Demand Side)
Figure 8 Market Sizing and Growth Forecast Approach
Figure 9 Global Digital Therapeutics Market Size, by Type, 2023 Vs. 2030 (USD Million)
Figure 10 Global Digital Therapeutics Market Size, by Application, 2023 Vs. 2030 (USD Million)
Figure 11 Global Digital Therapeutics Market Size, by End User, 2023 Vs. 2030 (USD Million)
Figure 12 Global Digital Therapeutics Market, by Geography
Figure 13 Global Digital Therapeutics Market: Impact Analysis
Figure 14 Germany: Reimbursement Approval Pathway
Figure 15 Global Digital Therapeutics Market, by Type, 2023 Vs. 2030 (USD Million)
Figure 16 Global Digital Therapeutics Market, by Applications, 2023 Vs. 2030 (USD Million)
Figure 17 Diabetes Patients, by Region 2021 Vs. 2030 Vs. 2045 (Million)
Figure 18 Drug Consumption Among the Population in 2020 (Million People)
Figure 19 Prevalence of Tobacco Use (% Of Adults) in 2020
Figure 20 Global Digital Therapeutics Market Size, by End User, 2023 Vs. 2030 (USD Million)
Figure 21 Digital Therapeutics Market, by Region, 2023 Vs. 2030 (USD Million)
Figure 22 North America: Digital Therapeutics Market Snapshot
Figure 23 U.S.: Number of People with Chronic Diseases, 2005-2030 (In Millions)
Figure 24 Europe: Digital Therapeutics Market Snapshot
Figure 25 Asia-Pacific: Digital Therapeutics Market Snapshot
Figure 26 Japan: Growth in Aging Population 2015-2021 (Million)
Figure 27 RoAPAC: Growth in Aging Population 2015 Vs. 2017 Vs. 2021 (Million)
Figure 28 Latin America: Digital Therapeutics Market Snapshot
Figure 29 Growth in the Elderly Population 2021 Vs. 2017 Vs. 2015
Figure 30 Key Growth Strategies Adopted by Leading Players, 2020–2023
Figure 31 Digital Therapeutics Market: Competitive Benchmarking (Based on Type)
Figure 32 Competitive Benchmarking for DTx: Based on DTx Capabilities and Therapeutic Area
Figure 33 Competitive Dashboard: Digital Therapeutics Market
Figure 34 Company Ranking: Digital Therapeutics Market (2022)
Figure 35 Resmed Inc.: Financial Snapshot (2022)
Figure 36 Teladoc Health, Inc.: Financial Overview (2022)
Figure 37 Dariohealth Corp.: Financial Snapshot (2022)
Figure 38 Akili, Inc.: Financial Snapshot (2022)
Published Date: Jul-2024
Published Date: Jun-2024
Published Date: Feb-2019
Published Date: Jul-2024
Please enter your corporate email id here to view sample report.
Subscribe to get the latest industry updates